Study reports REVLIMID activity in patients with relapsed/refractory mantle-cell lymphoma

December 09, 2008

the ORR and CR/CRu for 15 evaluable patients with MCL was 53 percent and 20 percent, respectively. The median duration of response seen in those patients was 13.7 months. The most common Grade 3 or 4 adverse events observed in MCL patients in the NHL-003 trial who received REVLIMID® were neutropenia (52%), thrombocytopenia (26%), anemia (13%), fatigue (10%) and febrile neutropenia (10%).

The company also reported pooled data on 14 MCL patients treated with REVLIMID from NHL-002 and NHL-003 who were previously treated with bortezomib, with seven of those patients being refractory to bortezomib. The data from this analysis demonstrated an ORR and CR of 57 percent and 21 percent, respectively, and a median PFS of 7.7 months. Bortezomib is the only drug approved in the US for patients with relapsed or refractory MCL and demonstrated an ORR and CR of 33 percent and 8 percent, respectively, in a pivotal study of patients with a median of one prior therapy.

"Patients with MCL are a particularly underserved population in need of new, effective treatment options," said Jean Pierre Bizarri, MD, Head of Global Clinical Oncology/Hematology for Celgene. "Based on these exciting Phase II results with REVLIMID in heavily pretreated MCL patients, Celgene has initiated a study which has undergone special protocol assessment - the EMERGE trial - in patients with relapsed/refractory MCL who have relapsed or progressed after treatment with bortezomib or are refractory to bortezomib and looks forward to presenting the results of this study at future meetings."

REVLIMID is currently approved in the European Union, United States, Canada, Argentina and Switzerland in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy and in Australia in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy. REVLIMID is also approved in Canada, the United States and Argentina for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID has obtained Orphan Drug designation in the EU, U.S., Switzerland, Australia and Japan.

REVLIMID is an IMiDs® compound, a member of a proprietary group of novel immunomodulatory agents. REVLIMID and other IMiDs continue to be evaluated in over 100 clinical trials in a broad range of hematological and oncological conditions. The IMiDs pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions, including composition-of- matter and use patents.

About Mantle-Cell Lymphoma

MCL is one of several subtypes of NHL and results from a malignant transformation of a B lymphocyte in the mantle zone - the outer edge of the lymph node follicles. The uncontrolled growth of the transformed lymphocytes, or lymphoma cells, cause tumors to form in the lymph nodes, which then become enlarged. Lymphoma cells can also spread to other tissues, such as the marrow, liver and gastrointestinal tract.

MCL is distinguished from other subtypes of B-cell lymphoma by abnormal expression of cyclin D1, a protein that stimulates cell growth. Approximately 85 percent of MCL cases are caused by genetic changes involving the cyclin D1 gene on chromosome 11 and chromosome 14.

About Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as Form 10-K, 10-Q and 8-K reports.

Weber Shandwick Worldwide

Related Anemia Articles from Brightsurf:

Study explores the association of malaria, HIV with anemia during pregnancy
Pregnant women from sub-Saharan Africa with malaria and human immunodeficiency virus (HIV) have a higher prevalence of anemia than pregnant women without infections, according to Penn State College of Medicine researchers.

Women with anemia twice as likely to need transfusion after cesarean delivery
Pregnant women with anemia are twice as likely to need blood transfusions after a cesarean delivery, as those without the condition, according to a study being presented at the ANESTHESIOLOGY® 2019 annual meeting.

Early maternal anemia tied to intellectual disability, ADHD and autism
The timing of anemia -- a common condition in late pregnancy -- can make a big difference for the developing fetus, according to research at Karolinska Institutet published in JAMA Psychiatry.

Anemia may contribute to the spread of dengue fever
Mosquitoes are more likely to acquire the dengue virus when they feed on blood with low levels of iron, researchers report in the 16 September issue of Nature Microbiology.

No bleeding required: Anemia detection via smartphone
Instead of a blood test, an app uses smartphone photos of someone's fingernails to accurately measure hemoglobin levels.

Malnutrition, anemia among Rohingya children in Bangladesh refugee camp
The pervasiveness of malnutrition and anemia among Rohingya children in a refugee camp in Bangladesh exceeds emergency thresholds.

Anemia: When cells fail to produce enough protein factories
Every day, stem cells in our bone marrow produce billions of new red blood cells.

Anemia discovery offers new targets to treat fatigue in millions
UVA has discovered an unknown biological process that controls the production of vital cells that carry oxygen throughout the body.

Fanconi anemia: Insight from a green plant
Fanconi anemia is a human genetic disorder with severe effects, including an increased risk of cancer and infertility.

New portable blood analyzer could improve anemia detection worldwide
To reduce the burden of anemia, health officials need a better picture of the disease's global impact, an understanding made viable by a portable and affordable way to analyze blood.

Read More: Anemia News and Anemia Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to